Add this topic to your myFT Digest for news straight to your inbox
Baseimmune aims to predict future pathogen mutations to create jabs that will be effective for longer
Drug developers raised $6bn in January, helped by a rebound in merger activity
Boston and Geneva-based enterprise believes new technology will transform dermatology
Sovereign wealth funds Temasek and Mubadala in talks to fund biotech groups harnessing mind-altering substances
Start-ups say new technology could help end animal testing by pharma companies
Danish biotech group Zealand Pharma is developing an alternative obesity treatment to compete with big rivals
‘Molecular factories’ boost field of synthetic biology, raising hopes of developing drugs and other products
Expanded genetic profiling could lead to breakthroughs in diagnosis and therapy for common tumours, landmark global study finds
Oxford university spinout working on polygenic risk scores to help predict disease
Argenx is one of the bloc’s largest biotech companies but its shareholder base is dominated by US specialist investors
Danish manufacturer of Wegovy invests in two start-ups as part of efforts to stay ahead in major new market
Lender invests in venture fund 4Bio Capital as it says UK sector has ‘significant untapped potential’
Sector benefits from shifts in interest rate expectations after 50% fall
Wuxi Biologics is likely to miss its original sales target for the year by about $400mn
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
How pension funds’ investments have impacted the London Stock Exchange
T-Therapeutics hopes to use genetically engineered rodents and machine learning to discover drugs
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
It’s the super-science revolutionising skincare. And it might help protect the planet
Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
US biotech has been struggling to overcome fall in demand for coronavirus jabs
UK Edition
